From the 1Mayo Clinic, Jacksonville, Florida, 2Yale University School of Medicine, New
Haven, Connecticut, 3Cleveland Clinic Lerner College of Medicine of Case Western …

In the era of communication technology, new options are now available for following-up
patients implanted with pacemakers (PMs) and defibrillators (ICDs). Most major companies …

Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected
patients in definable populations. The benefits and risks of ICD therapy are directly impacted …

Background—Monitoring performance of implantable cardioverter-defibrillator (ICD)
generators and leads is important. Methods available are with in-person evaluations or by …

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetic form of
cardiomyopathy (CM) usually transmitted with an autosomal dominant pattern. It primary …

The implantable-cardioverter defibrillator (ICD) lead is the most vulnerable component of the
ICD system. Despite advanced engineering design, sophisticated manufacturing …

Background—Approximately 268 000 Fidelis leads were implanted worldwide until
distribution was suspended because of a high rate of early failure. Careful analyses of …

Background Multicenter studies 1– 3 demonstrate that unnecessary implanted cardioverter
defibrillator (ICD) shocks can be reduced by evidence-based programming of detection rate …

Background—Downloadable software upgrades are common in consumer electronics but
not in implantable medical devices. Fractures of implantable cardioverter-defibrillator (ICD) …

The clinical benefits of pacemakers and implantable cardioverter defibrillators (ICDs) have
been well-established by numerous scientific studies. 1–23 Millions of devices have been …